Healthcare provider profile · identity verified

Katie Danielle Buckner, DO

Family Practice · ABINGDON, VA · NPI 1558891101

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	576	212
Lisinopril	Lisinopril	333	128
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	274	74
Amlodipine Besylate	Amlodipine Besylate	243	99
Levothyroxine Sodium	Levothyroxine Sodium	243	91
Albuterol Sulfate Hfa	Albuterol Sulfate	228	81
Losartan Potassium	Losartan Potassium	223	86
Gabapentin	Gabapentin	177	66
Metformin Hcl	Metformin Hcl	157	57
Hydrochlorothiazide	Hydrochlorothiazide	146	56
Rosuvastatin Calcium	Rosuvastatin Calcium	139	67
Pantoprazole Sodium	Pantoprazole Sodium	131	49
Alendronate Sodium	Alendronate Sodium	128	57
Metformin Hcl Er	Metformin Hcl	127	50
Tramadol Hcl	Tramadol Hcl	127	37
Glipizide	Glipizide	113	44
Atenolol	Atenolol	109	36
Tamsulosin Hcl	Tamsulosin Hcl	108	36
Omeprazole	Omeprazole	104	52
Trazodone Hcl	Trazodone Hcl	102	44
Ibuprofen	Ibuprofen	96	44
Simvastatin	Simvastatin	90	31
Metoprolol Tartrate	Metoprolol Tartrate	86	33
Meloxicam	Meloxicam	76	23
Ozempic	Semaglutide	72	23
Humulin N	Insulin Nph Human Isophane	66	20
Pradaxa	Dabigatran Etexilate Mesylate	65	23
Clopidogrel	Clopidogrel Bisulfate	60	24
Duloxetine Hcl	Duloxetine Hcl	51	24
Topiramate	Topiramate	47	18
Finasteride	Finasteride	44	17
Potassium Chloride	Potassium Chloride	44	26
Buspirone Hcl	Buspirone Hcl	43	21
Jardiance	Empagliflozin	43	18
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	43	16
Prednisone	Prednisone	43	37
Spiriva Respimat	Tiotropium Bromide	42	11
Furosemide	Furosemide	40	22
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	40	14
Ondansetron Hcl	Ondansetron Hcl	39	11
Sertraline Hcl	Sertraline Hcl	39	14
Mirtazapine	Mirtazapine	38	19
Zolpidem Tartrate	Zolpidem Tartrate	38	suppressed
Hydrocortisone	Hydrocortisone	36	17
Metoprolol Succinate	Metoprolol Succinate	36	19
Humulin N Kwikpen	Insulin Nph Human Isophane	35	12
Terazosin Hcl	Terazosin Hcl	34	15
Lorazepam	Lorazepam	33	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	33	13
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	31	13
Triamcinolone Acetonide	Triamcinolone Acetonide	31	25
Alprazolam	Alprazolam	30	suppressed
Lubiprostone	Lubiprostone	30	suppressed
Allopurinol	Allopurinol	29	13
Estradiol	Estradiol	29	11
Famotidine	Famotidine	29	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	29	suppressed
Montelukast Sodium	Montelukast Sodium	28	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	28	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	27	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	27	13
Temazepam	Temazepam	26	suppressed
Baclofen	Baclofen	25	suppressed
Cephalexin	Cephalexin	25	25
Hydralazine Hcl	Hydralazine Hcl	25	12
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	25	suppressed
Azelastine Hcl	Azelastine Hcl	23	suppressed
Azithromycin	Azithromycin	23	22
Lactulose	Lactulose	23	suppressed
Ondansetron Odt	Ondansetron	23	13
Trospium Chloride	Trospium Chloride	23	11
Bupropion Xl	Bupropion Hcl	21	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	21	suppressed
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	20	20
Tizanidine Hcl	Tizanidine Hcl	20	suppressed
Fluticasone Propionate	Fluticasone Propionate	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	19	suppressed
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	19	suppressed
Fluocinonide	Fluocinonide	18	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	18	suppressed
Alvesco	Ciclesonide	17	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	17	17
Escitalopram Oxalate	Escitalopram Oxalate	17	suppressed
Naproxen	Naproxen	17	suppressed
Nystatin	Nystatin	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	16
Acetaminophen-Codeine	Acetaminophen With Codeine	16	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	16	15
Hydroxyzine Hcl	Hydroxyzine Hcl	16	11
Lovastatin	Lovastatin	16	suppressed
Risedronate Sodium	Risedronate Sodium	16	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	15	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	15	15
Eliquis	Apixaban	15	suppressed
Fluconazole	Fluconazole	15	13
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Citalopram Hbr	Citalopram Hydrobromide	14	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Rizatriptan	Rizatriptan Benzoate	14	suppressed
Liraglutide	Liraglutide	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	11
Victoza 2-Pak	Liraglutide	13	suppressed
Nifedipine Er	Nifedipine	12	suppressed
Ofloxacin	Ofloxacin	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Carvedilol	Carvedilol	11	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	11	suppressed
Naltrexone Hcl	Naltrexone Hcl	11	suppressed
Raloxifene Hcl	Raloxifene Hcl	11	suppressed
Sucralfate	Sucralfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error